April 2014
UCURRICULUM VITAE
Quintin Pan, PhD
PERSONAL:
Address:OfficeLaboratory
442 Tzagournis446-450 Tzagournis
420 West 12th Avenue
The OhioStateUniversityMedicalCenter
Columbus, OH 43210
Phone: (614)247-4438
Fax: (614)688-4761
Email:
EDUCATION:
1989-1993Rensselaer Polytechnic Institute, Troy, New York
Degree: BS in Biology
1994-1999University of MichiganMedicalSchool, Ann Arbor, Michigan
Degree: PhD in Pharmacology
1BPOSTGRADUATE TRAINING:
2B2000-2003Postdoctoral Fellow, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
ACADEMIC APPOINTMENTS:
1997Teaching Assistant (course: Nursing Pharmacology), University of Michigan Medical School, Ann Arbor, Michigan
2003-2006Research Investigator (research faculty), Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan
2007-2008Assistant Professor, Department of Otolaryngology,
Division of Head and Neck Surgery, University of MichiganMedicalSchool, Ann Arbor, Michigan
2007-2008Assistant Professor, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan
2008-presentAssociate Professor, Department of Otolaryngology-Head and Neck
Surgery, The OhioStateUniversity Medical Cancer, Columbus, Ohio
2008-presentResearch Director, Head and Neck Oncology Program, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical Center, Columbus, Ohio
HONORS AND AWARDS:
1991National Institutes of Health Undergraduate Research Fellowship
1992 National Dean’s List
1992 Rensselaer Undergraduate Research Award
1997Newton-Loeb/University of MichiganComprehensiveCancerCenter Predoctoral Fellowship
1997Young Investigator’s Travel Award for Vitamin D Conference
1997ASPET Predoctoral Travel Award
2001NIH T32 Cancer Biology Training Program Postdoctoral Fellowship
2001Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship
2001Central Society for Clinical Research Travel Award
2002USAMRMC Breast Cancer Program Postdoctoral Trainee Award
2004NIH/NCI Head and Neck SPORE Career Development Award
2004USAMRMC Breast Cancer Program Concept Award
2008 FAMRI Young Clinical Scientist Award
2008 American Cancer Society Research Scholar
2010The Michelle Theado Memorial Grant, Joan Bisesi Fund for Head and Neck Oncology Research
2011-presentMember, Head and Neck Cancer Metastatic and Recurrent Disease Task Force, National Cancer Institute
ADMINISTRATIVE AND COMMITTEE SERVICE:
Departmental:
2007-2008Member, Research Committee, Department of Otolaryngology, University of MichiganMedicalSchool
2008-presentMember, Research Committee, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical School
2009-presentMember, Head and Neck Fellowship Selection Committee, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical School
2012-present Member, Otolaryngology Resident Selection Committee, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical School
National:
2011-presentMember, Head and Neck Cancer Metastatic and Recurrent Disease Task Force, National Cancer Institute
EDITORIAL POSITIONS AND BOARDS:
Editorial board, Cancer Research (2013-present)
Editorial board, Biomed Research International (2013-present)
Editorial board, Anaplastology (2012-present)
Editorial board, ISRN Oncology (2011-present)
Editorial board, Otolaryngology (2011-present)
Ad hoc reviewer, Cancer Research
Ad hoc reviewer, Clinical Cancer Research
Ad hoc reviewer, Stem Cells
Ad hoc reviewer, Cancer Epidemiology, Biomarkers, and Prevention
Ad hoc reviewer, Cancer
Ad hoc reviewer, Oral Oncology
Ad hoc reviewer, ACS Nano
Ad hoc reviewer, ACS Chemical Biology
Ad hoc reviewer, PLOS One
Ad hoc reviewer, Breast Cancer Research and Treatment
Ad hoc reviewer, European Journal of Surgical Oncology
Ad hoc reviewer, Clinical and Experimental Metastasis
Ad hoc reviewer, The Journal of Investigative Dermatology
Ad hoc reviewer, Molecular Cell Research
Ad hoc reviewer, Molecular Carcinogenesis
Ad hoc reviewer, Clinical Medicine Reviews in Oncology
Ad hoc reviewer, Cancer Management and Research
Ad hoc reviewer, Expert Opinion on Pharmacotherapy
Ad hoc reviewer, Journal of Dental Research
Ad hoc reviewer, Molecular Biology Reports
Ad hoc reviewer, International Journal of Otolaryngology
Ad hoc reviewer, Current Cancer Drug Targets
Ad hoc reviewer, International Journal of Biochemistry and Cell Biology
Ad hoc reviewer, Head Neck
Ad hoc reviewer, Translational Oncology
PEER-REVIEW SERVICE:
2008Ad hoc reviewer, Prostate Cancer Foundation of Australia
2009Ad hoc reviewer, National Institutes of Health, Special Emphasis Panel,
Special Topics in Biological Sciences, ZRG1 OBT-A(58)R
2000-2011Ad hoc reviewer, James and Esther King Biomedical Research Program Florida Department of Health
2010-2011Ad hoc reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Health
2013 Ad hoc reviewer, Individual Research Grants, Israel Science Foundation
2013Ad hoc reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Health
2013-presentAd hoc member, National Institutes of Health, Oral, Dental, and Craniofacial Sciences Scientific Review Group (ODCS)
2013-presentAd hoc member, National Institutes of Health, Special Emphasis Panel, ZRG1 MOSS-K(80)S
TEACHING ACTIVITIES
1997-1998Lecturer, “Endocrine Pharmacology”, Nursing Pharmacology Course, University of Michigan
2011Lecture, “Molecular Determinants of Head and Neck Cancer”, Otolaryngology Resident Lecture Series, The OhioStateUniversityMedicalCenter
2012Lecture, “How to Write a NIH Grant?”, Otolaryngology Resident Lecture Series, The OhioStateUniversityMedicalCenter
2012Lecture, “Cancer Stem Cells”, Special Topics in Cancer Course, The OhioStateUniversity
2012Lecture, “Head and Neck Cancer Stem Cells”, Otolaryngology Resident Lecture Series, The OhioStateUniversityMedicalCenter
2013Lecture, “Integration of Next Generation Sequencing Technology for Personalized Medicine”, Otolaryngology Resident Lecture Series, The OhioStateUniversityMedicalCenter
3BMEMBERSHIPS IN PROFESSIONAL SOCIETIES
American Association for Cancer Research
0BAmerican Society for Pharmacology and Experimental Therapeutics
GRANT SUPPORT
Active:
Sponsor:NIH/NCI-R01CA135096
Role:Principal Investigator
Title:Role of PKC in Oral Cancer
Total Project Period:08/01/08-05/31/14 (NCE)
Total Direct Costs:$1,037,500
Sponsor:NIH/NCI-R01CA140667
Role:Co-Investigator
Title:Small Molecule Inhibitors of the Transcriptional Activators ESX and NFB
Total Project Period:05/20/09-02/28/14
Total Direct Costs:$1,037,500
Sponsor:National Comprehensive Cancer Network
Role:Co-Investigator
Title:Use of Vorinostat for Definitive Treatment of Advanced Stage Oropharyngeal Squamous Cell Carcinoma
Total Project Period:07/01/09-06/30/13
Total Direct Costs:$300,000
Sponsor:NIH/NCI-T32CA009338
Role:Trainee Mentor
Title:Oncology Training Grant
Total Project Period:08/01/10-06/30/15
Completed:
Sponsor:American Cancer Society-Research Scholar Grant
Role:Principal Investigator
Title:Mechanism of PKC-induced Tumorigenesis in Head and Neck Cancer
Total Project Period:07/01/08-06/30/12
Total Direct Costs:$600,000
Sponsor: NIH/NCI-Contract Grant
Role: Co-Investigator
Title: Development of Oral Allosteric PKC Inhibitors for Head and Neck Cancer Therapy
Total Project Period: 09/30/10-06/30/11
Total Direct Costs: $57,460
Sponsor:FAMRI-Young Clinical Scientist Award
Role:Principal Investigator
Title:Development of PKC Inhibitors for Treating Head and Neck Cancer
Total Project Period:07/01/08-06/30/11
Total Direct Costs:$300,000
Sponsor:NIH/NCI Head and Neck SPORE
Role:Principal Investigator/Career Development Award
Title:Role of PKC in Establishing an Aggressive Phenotype in Head and Neck Squamous Cell Carcinoma
Total Project Period:07/01/04-06/30/08 (no cost extension to 06/30/08)
Total Direct Costs:$247,500
Sponsor:USAMRMC Breast Cancer Research Program
Role:Principal Investigator/Concept Award
Title:Are Breast Tumor Stem Cells Responsible for Metastasis and Angiogenesis?
Total Project Period:09/01/04-08/31/06
Total Direct Costs:$75,000
Sponsor:USAMRMC Breast Cancer Research Program
Role:Principal Investigator/Postdoctoral Trainee Award
Title:Suppression of NFB Activity by Tetrathiomolybdate Inhibits Tumor Angiogenesis and Enhances Apoptosis in Breast Cancer
Total Project Period:05/01/02-04/30/05
Total Direct Costs:$149,893
Sponsor:Susan G. Komen Breast Cancer Foundation
Role:Postdoctoral Fellowship for Quintin Pan, Ph.D. (PI: Sofia D. Merajver, M.D., Ph.D.)
Total Project Period:10/01/01-09/30/04 (transferred due to overlapping support)
Total Direct Costs:$105,000
Sponsor: NIH T32 University of MichiganMedicalSchool Cancer Biology Postdoctoral Training Grant
Role:Postdoctoral Fellowship for Quintin Pan, Ph.D. (PI: Michael J. Imperiale, Ph.D.)
Total Project Period:05/01/01-04/30/02
Total Direct Costs: $35,000
4BBIBLIOGRAPHY:
5BPeer-Reviewed Publications:
1.Pan Q, Martell RE, O’Connell TD and Simpson RU (1996) 1,25-Dihydroxyvitamin D3 regulated binding of nuclear proteins to a c-myc intron element. Endocrinology 137:4154-4160.
2.Pan Q, Granger J, O’Connell TD, Somerman MJ and Simpson RU (1997) Promotion of HL-60 cell differentiation by 1,25-dihydroxyvitamin D3 regulation of PKC activity and levels. Biochem. Pharm. 54:909-915.
3.Simpson RU, O’Connell TD, Pan Q, Newhouse J and Somerman MJ (1998) Antisense oligonucleotides targeted against protein kinase C and block 1,25-(OH)2D3 induced HL-60 cell differentiation. J. Biol. Chem. 273:19587-19591.
4.Pan Q and Simpson RU (1999) c-myc intron element binding proteins are required for 1,25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation: Involvement of HOXB4. J. Biol. Chem. 274:8437-8444.
5.Hullinger TG, Pan Q, Viswanathan HL and Somerman MJ (2001) TGF and BMP-2 activation of the osteopontin promoter: role of Smad and Hox binding proteins. Exp. Cell Res. 262:69-74.
6.Pan Q and Simpson RU (2001) Antisense knockout of HOXB4 blocks 1,25-dihydroxyvitamin D3 inhibition of c-myc expression. J. Endo. 169:153-159.
7.van Golen KL, Bao LW, Pan Q, Miller F, Wu ZF and Merajver SD (2002) Activation of the mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenic factor production in inflammatory breast cancer. Clin. Exp. Metastasis. 19:301-311.
8.Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF and Merajver SD (2002) WISP3, a novel tumor suppressor gene for inflammatory breast cancer. Oncogene. 21:3172-3180.
9.Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ and Merajver SD (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62:4854-4859.
10.Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ and MerajverSD (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer Res.9:1666-1672.
11.Pan Q, Bao LW, Kleer CG, Brewer GJ and MerajverSD (2003) Antiangiogenic tetrathiomolybdate enhances doxorubicin therapy against breast carcinoma. Mol. Cancer Ther. 2:617-622.
12.Pan Q, Bao LW and MerajverSD (2003) Tetrathiomolybdate inhibits tumor angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol. Cancer Res. 1:701-706.
13.Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF and MerajverSD (2004) WISP3 and RhoC-GTPase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 6:R110-115.
14.Kleer CG, Zhang Y, Pan Q and MerajverSD (2004) WISP3 is a secreted tumor suppressor protein that modulates IFG signaling in inflammatory breast cancer. Neoplasia 6:179-185.
15.Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD and Teknos TN (2004) Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101:2779-2787.
16.Teknos TN, Islam M, Arenberg DA, Pan Q, Carskadon SL, Abarbanell AM, Marcus B, Paul S, Vandenberg CD, Carron M, Nor JE and Merajver SD (2005) The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 131: 204-211.
17.Pan Q*, Bao LW, Kleer CG, Sabel MS, Griffith KA, TeknosTN and MerajverSD (2005) Protein kinase Cε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anti-cancer therapy. Cancer Res. 65:8366-8371. *corresponding author
18.Zhang Y, Pan Q, Zhong H, MerajverSD and Kleer CG (2005) Inhibition of CCN6 (WISP3) expression promotes neoplastic transformation and enhances the effects of IGF-1 on breast epithelial cells. Breast Cancer Res. 7:R1080-1089.
19.Kleer CG, Teknos TN, Islam M, Marcus B, Lee J, Pan Q and Merajver SD (2006) RhoC GTPase expression as a potential marker of lymph node metastasis in squamous carcinoma of the head and neck. Clin. Cancer Res. 12:4485-4490.
20.Pan Q*, Bao LW, TeknosTN and MerajverSD (2006) Targeted disruption of PKCε reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 66:9379-9384.*corresponding author
21.Hassouneh B, Islam M, Nagel T, Pan Q, MerajverSD and TeknosTN (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol. Cancer Ther. 6:1039-1045.
22.Henry LN, Dunn RL, Merajver SD, Pan Q, Pienta KJ, Brewer GJ and Smith DC (2007) Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology 71:168-175. Epub 2007 July 18.
23.Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JMG, Pan Q, Carey TE, Bradford CR, Prince ME, Cordell KG, Kirkwood KL and D’Silva NJ (2008) Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 68:3959-3969.
24.Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD and Zalupski MM (2009) A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest. New Drugs 27:159-165.
25.Gorin MA and Pan Q (2009) Protein kinase C: an oncogene and emerging tumor biomarker. Mol. Cancer 8:9. Epub 2009 Feb 19.
26.Bao LW, Gorin MA, Zhang M, Ventura AC, Pomerantz WC, Merajver SD, Teknos TN, Mapp AK and Pan Q (2009) Preclinical development of a bifunctional cancer cell homing, PKC inhibitory peptide for the treatment of head and neck cancer. Cancer Res. 69:5829-5834.
27.Pan Q*, Gorin MA and TeknosTN (2009) Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opin. Pharmacother. 10:2291-2302. *corresponding author
28.Khan GN, Gorin MA, Rosenthal D, Pan Q, Bao LW, Wu ZF, Newman RA, Pawlus AD, Yang P, Lansky EP and MerajverSD (2009) Pomegranate fruit extract impairs invasion and motility in human breast cancer. Integr. Cancer Ther. 8:242-253.
29.Lee LW, Taylor CE, Desaulniers JP, Zhang M, Hojfeldt JW, Pan Q and MappAK (2009) Inhibition of ErbB2 (Her2) expression with small molecule transcription factor mimics. Bioorg. Med. Chem. Lett. 19:6233-6236.
30.Pan Q*, Rosenthal D, Kleer CG, Bao LW and MerajverSD (2009) Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic modeling of the mammary gland. Clin. Cancer Res.15:7441-7446.*corresponding author
31.Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, Kumar P and Teknos TN (2009) RhoC expression and head and neck metastasis. Mol. Cancer Ther. 11:1771-1780.
32.Kumar P, Yadav A, Patel SN, Islam M, Pan Q, MerajverSD and TeknosTN (2010) Tetrathiomolybdate inhibits head and neck metastasis by decreasing tumor cell motility, invasiveness, and by promoting tumor cell anoikis. Mol. Cancer 9:206.
33.Bhave S, TeknosTN and Pan Q (2011) Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr.21:143-153.
34.Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN and Pan Q (2012) microRNA-107 functions as a candidate tumor suppressor gene in head and neck squamous cell carcinoma by down-regulation of protein kinase Cε. Oncogene. 36:4045-4053.
35.Taylor CE, Pan Q and MappAK (2012) Synergistic enhancement of the potency and selectivity of small molecule transcriptional inhibitors. ACS Med Chem Lett. 3:30-34.
36.Piao L, Zhang M, Datta J, Xie X, Su TZ, Li H, TeknosTN and Pan Q (2012) Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther. 6:1261-1269.
37.Smith A, TeknosTN and Pan Q (2013) Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 49:287-292.
38.Xie X, Piao L, Bullock BN, Smith A, Su TZ, Zhang M, TeknosTN, Arora PS and Pan Q (2013) Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma.Oncogene. doi: 10.1038/onc.2013.25.
39.Tassone P, Old M, Teknos TN and Pan Q (2013) p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol. 49:733-7.
40.Xie X, Piao L, Cavey GS, Old M, TeknosTN, MappAK and Pan Q (2013) Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis. Oncogene. doi: 10.1038/onc.2013.173.
41.Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, Su TZ, Lang JC, Xie X, TeknosTN, MappAK and Pan Q (2013) Genetic and chemical targeting of epithelial-restricted with serine box reduces epidermal growth factor receptor and potentiates the efficacy of afatinib. Mol. Cancer Ther. 12:1515-25. doi: 10.1158/1535-7163.MCT-12-1110. Epub 2013 May 30.
42.Su TZ, Straight S, Bao LW, Xie X, Lehner CL, Cavey GS, Teknos TN and Pan Q (2013) PKCεphosphorylates and mediates the cell membrane localization of RhoA. ISRN Oncol. 2013:329063. doi: 10.1155/2013/329063. PMID:24191200; PMCID:PMC3804392
43.Zhang M, Kumar B, Xie X, Piao L, Schmitt A, Arradaza N, Old M, Agrawal A, Ozer E, SchullerDE, TeknosTN and Pan Q (2014) Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. doi: 10.1002/cncr.28538. [Epub ahead of print] PMID:24382806
44.Santaliz-Ruiz L, Xie X, Old M, Teknos TN and Pan Q (2014) Emerging role of Nanog in tumorigenesis and cancer stem cells. Int. J. Cancer. doi: 10.1002/ijc.28690. [Epub ahead of print] PMID:24375318
45.Xie X, TeknosTN and Pan Q (2014) Are all cancer stem cells created equal? Stem Cells Transl. Med.Submitted.
46.Santaliz-Ruiz L, TeknosTN and Pan Q (2014) Afatinib, a dual EGFR/Her2 tyrosine kinase inhibitor, inhibits the proliferation of EGFR+ and EGFR- head and neck squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. Submitted.
47.Doss C, Clayton J, Pan Q and MappAK (2014) Small molecule inhibitors of cancer initiating cells: Chemical tools for modern cancer biology. ACS Chem. Biol. Submitted.
48.Old M, Yu J, Yoo JY, Kaka A, Pan Q, Kumar P, Kumar B, Mazar AP, Teknos TN and Kaur B (2014) ATN-224 enhances anti-tumor efficacy of oHSV expressing Vstat120 against local and metastatic head and neck squamous cell carcinoma. Mol Ther. Submitted.
Book Chapters:
- Pan Q, Martell RE, O’Connell TD, and Simpson RU. “1,25-Dihydroxyvitamin D3 regulation of c-myc expression and MIE binding proteins during HL-60 cell differentiation.” In: Vitamin D. Chemical, Biochemical, and Clinical Update. (Ed. A.W. Norman) Walter DeGrueyler, Berlin, 1997.